Healthcare AI Safety Gap · Don't break patients
    Peer-reviewed / official18 Aug 2026·US

    FDA opens the question it hasn't answered: how to regulate generative-AI devices

    The FDA published a discussion paper and public docket on regulating generative-AI medical devices, proposing to test them through a 'competency assessment' modelled on how physicians are trained, and asking the field how it should work.

    19 Oct 2026
    deadline for public comment on how generative-AI medical devices should be evaluated before and after they reach patients

    What the research found

    The FDA's Digital Health Center of Excellence issued a discussion paper acknowledging that generative-AI-enabled devices may introduce risks unlike those of traditional software or earlier AI devices, and opened docket FDA-2026-N-7874 for comment until 19 October 2026. It sketches a two-axis risk framework, a premarket approach built on 'competency assessment' (non-clinical benchmarking plus clinical confirmation, inspired by how physicians are trained and examined) and several options for risk-proportionate postmarket monitoring, including for foundation models and agentic systems. CDRH director Michelle Tarver framed it as a transparent process intended to serve as a potential model for regulators elsewhere.

    Why it matters for providers

    Generative AI is already in clinical settings while the framework for judging it is still being drafted in public, which is both the clearest statement yet that clearance is not proof, and an open door for providers to say what evidence they'd actually need.

    Original source
    U.S. FDA, Digital Health Center of Excellence, Center for Devices and Radiological Health
    Read the full report ↗
    Peer-reviewed or official source, the most reliable tier.